NCT06599918View on ClinicalTrials.gov

Study of the Efficacy and Safety of Nicotinamide in Patients with Diabetes Mellitus Type 2 and Liver Fibrosis (NICOFIB)

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 23, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Fatty LiverObesityDiabete Type 2Hepatic FibrosisNAFLDNicotinamide
Interventions
DRUG

Nicotinamide

Administration of NAM on a variable dose depending on the participant's body weight. Administration is done orally, daily.

DRUG

Placebo

Administration of placebo on a variable dose depending on the participant's body weight. Administration is done orally, daily.

Trial Locations (1)

08025

RECRUITING

Hospital de la Santa Creu i Sant Pau, Barcelona

All Listed Sponsors
collaborator

Germans Trias i Pujol Hospital

OTHER

lead

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

OTHER